ZCCHC9 promotes proliferation and invasion of lung cancer through regulating the JNK pathway

Shi, Xiuying; Jiang, Bao-guo; Liu, Haifeng; Fan, Chuifeng

doi:10.1002/jcb.28346

Cited by 8 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 It has been widely reported that many key genes affecting lung cancer function through these two pathways. 60,61 In this study, changes in HBA and HBB affected the synthesis of p38 and JNK proteins, suggesting that they may also have a similar mechanism of action. which is a new starting point on searching for biomarkers.…”

Section: Discussionmentioning

confidence: 50%

Role of hemoglobin alpha and hemoglobin beta in non‐small‐cell lung cancer based on bioinformatics analysis

Kang

Qiu

Wang

et al. 2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

The differentially expressed genes (DEGs) were identified and screened differentially in non‐small‐cell lung cancer (NSCLC) using information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases, and the correlation of DEGs in protein interaction, function, and pathway enrichment were analyzed to search for new biomarkers and potential therapeutic targets for NSCLC. Protein–protein interaction network (PPI) analysis showed that CDK1 and GNGT1 were the most significantly upregulated hub nodes, while FPR2 was the most significantly downregulated. Gene Ontology enrichment analysis showed that upregulated DEGs were significantly enriched in protein heterodimerization activity and other functions, while downregulated DEGs were enriched in functions such as heparin‐binding. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that upregulation of DEGs were significantly associated with neuroactive ligand‐receptor interaction pathways, while downregulation of DEGs were significantly associated with malaria pathways. According to the analysis results, we identified hemoglobin alpha (HBA) and hemoglobin beta (HBB) as the genes of interest for further study. Through tissue level and cell level experiments, we found that the expressions of HBA and HBB in NSCLC tissues were significantly lower than those in paracancerous tissues, and downregulation of HBA and HBB could significantly affect the proliferation ability of NSCLC cells. In addition, we also found that changes in HBA and HBB may affect NSCLC cells through the p38/MAPK pathway and JNK pathway, and ultimately affect the occurrence and development of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 50%

Role of hemoglobin alpha and hemoglobin beta in non‐small‐cell lung cancer based on bioinformatics analysis

Kang

Qiu

Wang

et al. 2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…It also up-regulates the JNK pathway activity in the MAPK pathway subfamily in lung cancer cells such as A549 and NCI-H1299 to promote the proliferation and invasion of cancer cells. 24,30 This indicates that ZCCHC9 has a potential role in the MAPK signaling cascade. Oxidative stress, that is, reactive oxygen species that mediate a series of biochemical reactions in cells through MAPK signaling pathways, is related to AMI.…”

Section: Discussionmentioning

confidence: 96%

Low ZCCHC9 Gene Expression in Peripheral Blood May Be an Acute Myocardial Infarction Genetic Molecular Marker in Patients with Stable Coronary Atherosclerotic Disease

Li¹,

Meng²,

Wang³

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose ZCCHC9 is a zinc finger protein with a CCHC zinc finger structure and has important roles in several cellular processes. This study was conducted on an expanded number of samples to evaluate The usefulness of ZCCHC9 gene expression in peripheral blood as a molecular marker for the prediction of AMI (acute myocardial infarction) risk. Patients and Methods Peripheral blood samples were collected from 117 patients with stable CAD (coronary atherosclerotic disease) and 126 patients with AMI. The mRNA level of the ZCCHC9 gene was assessed by qRT-PCR, and its protein level was determined by Western blotting. Results The AMI group exhibited reduced expression of the ZCCHC9 gene, at both transcript and protein levels, than the stable CAD group. The low expression of the ZCCHC9 gene was not related to blood glucose level (P=0.635), blood lipid level, and troponin level (P=0.715), and may cause AMI through the MAPK signaling pathway. Compared with other patients, patients with low ZCCHC9 gene expression in their peripheral blood have a 2.597-fold higher risk of AMI. Conclusion ZCCHC9 gene expression in peripheral blood was significantly lower in patients with AMI than in stable CAD patients. Individuals with low expression of ZCCHC9 in peripheral blood have higher a probability to develop AMI than those with stable CAD. Thus, lowered ZCCHC9 gene expression can act as an independent risk factor for AMI.

show abstract

“…Studies have shown that CCHC‐type zinc finger proteins play biological functions in tumour tissues via regulating the MAPK signalling pathway 2‐5 composed of ERK1/2, P38, ERK5 and JNK 18 . While ZCCHC14 is a protein containing multiple zinc finger motifs, there are no studies on its possible involvement in the signalling pathway.…”

Section: Discussionmentioning

confidence: 99%

“…Transwell assays were performed as described 11 . Cell suspensions (100 µl containing 1 × 10 4 cells) were placed in the upper chamber and were then incubated for an additional 24 hours. Cells appearing on the lower surface of the filter were stained with crystal violet and five random fields were counted using a high‐magnification microscope.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

ZCCHC14 regulates proliferation and invasion of non–small cell lung cancer through the MAPK‐P38 signalling pathway

Shi

Han

Cao

et al. 2020

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

ZCCHC14 is a CCHC‐type zinc finger protein which is expressed in tissues in human and mouse. The function of ZCCHC14 in tumours remains unclear. In this research, we explored the expression, function and related molecular mechanisms of ZCCHC14 in human non–small cell lung cancer (NSCLC). Immunochemistry staining showed that ZCCHC14 was low‐expressed or absent in NSCLC tissues. In NSCLC patients, the low expression of ZCCHC14 in tumour tissues was significantly correlated with TNM stage, differentiation degree and adverse clinical outcome ( P < .05). The proliferation and invasion ability of cancer cells transfected with ZCCHC14 CRISPR/Ca9 KO plasmids was significantly enhanced ( P < .05). Immunoblotting analysis indicated that the expression of p‐P38, cyclinD1 and MMP7 were significantly up‐regulated after disabling ZCCHC14 ( P < .05). We used MAPK‐P38 pathway inhibitor doramapimod (BIRB 796) to inhibit P38 signalling pathway activity and determined that the agent significantly disrupted the function of ZCCHC14 and hindered the proliferation and invasion of the tumour. The finding revealed that ZCCHC14 can regulate proliferation and invasion of NSCLC through the P38 pathway. ZCCHC14 plays a crucial regulatory role in the development of NSCLC and may become a zinc finger target for clinical treatment.

show abstract

ZCCHC9 promotes proliferation and invasion of lung cancer through regulating the JNK pathway

Cited by 8 publications

References 14 publications

Role of hemoglobin alpha and hemoglobin beta in non‐small‐cell lung cancer based on bioinformatics analysis

Role of hemoglobin alpha and hemoglobin beta in non‐small‐cell lung cancer based on bioinformatics analysis

Low ZCCHC9 Gene Expression in Peripheral Blood May Be an Acute Myocardial Infarction Genetic Molecular Marker in Patients with Stable Coronary Atherosclerotic Disease

ZCCHC14 regulates proliferation and invasion of non–small cell lung cancer through the MAPK‐P38 signalling pathway

Contact Info

Product

Resources

About